The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia

Adibhatla, 2001, Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia, Stroke, 32, 2376, 10.1161/hs1001.096010 Alvarez, 1999, Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion, Methods and Findings in Experimental and Clinical Pharmacology, 21, 633, 10.1358/mf.1999.21.9.795632 Alvarez-Sabín, 2013, Long-term treatment with citicoline may improve poststroke vascular cognitive impairment, Cerebrovascular Diseases, 35, 146, 10.1159/000346602 Amenta, 2012, The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: Interim results, Journal of the Neurological Sciences, 15, 96, 10.1016/j.jns.2012.07.003 Caamaño, 1994, Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease, Methods and Findings in Experimental and Clinical Pharmacology, 16, 211 Cacabelos, 1993, Effect of CDP-choline on cognition and immune function in Alzheimer’s disease and multi-infarct dementia, Annals of the New York Academy of Sciences, 695, 321, 10.1111/j.1749-6632.1993.tb23076.x Cacabelos, 1999, The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer’s disease, International Journal of Geriatric Psychiatry, 14, 3, 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7 Castagna, 2016, The CITIRIVAD study: CITIcoline plus RIVAstigmine in elderly patients affected with dementia study, Clinical Drug Investigation, 36, 1059, 10.1007/s40261-016-0454-3 Cook, 2018, The unique benefits of citicoline: An emerging nootropic and brain health nutrient, Natural Medicine Journal Cotroneo, 2013, Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study, Clinical Interventions in Aging, 8, 131 D’Orlando, 1995, Citicoline (CDP-choline): Mechanism of action and effects in ischemic brain injury, Neurological Research, 17, 281, 10.1080/01616412.1995.11740327 Deardorff, 2016, A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease, Drug Design, Development and Therapy, 10, 3267, 10.2147/DDDT.S86463 Dubois, 2010, Revising the definition of Alzheimer’s disease: A new lexicon, The Lancet Neurology, 9, 1118, 10.1016/S1474-4422(10)70223-4 Farrimond, 2012, Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: A systematic review, BMJ Open, 2, 10.1136/bmjopen-2012-000917 Fernández-Novoa, 1994, CDP-choline-induced blood histamine changes in Alzheimer’s disease, Methods and Findings in Experimental and Clinical Pharmacology, 16, 279 Fioravanti, 2005, Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly, The Cochrane Database of Systematic Reviews, 18 Gareri, 2017, The Citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with alzheimer’s disease study, Journal of Alzheimer’s Disease: JAD, 56, 557, 10.3233/JAD-160808 Gareri, 2014, Retrospective study on the benefits of combined memantine and cholinEsterase inhibitor treatMent in AGEd patients affected with alzheimer’s disease: The MEMAGE study, Journal of Alzheimer’s Disease: JAD, 41, 633, 10.3233/JAD-132735 García-Cobos, 2010, Citicoline, use in cognitive decline: Vascular and degenerative, Journal of the Neurological Sciences, 299, 188, 10.1016/j.jns.2010.08.027 Gareri, 2015, The role of citicoline in cognitive impairment: Pharmacological characteristics, possible advantages and doubts for an old drug with new perspectives, Clinical Interventions in Aging, 10, 1421, 10.2147/CIA.S87886 Gutierrez-Fernandez, 2012, CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke, Neurochemistry International, 60, 310, 10.1016/j.neuint.2011.12.015 Hurtado, 2011, Neuroprotection and recovery: Recent data at the bench on citicoline, Stroke, 42, S33, 10.1161/STROKEAHA.110.597435 Hurtado, 2005, Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: Effects on glutamate transport, Neurobiology of Disease, 18, 336, 10.1016/j.nbd.2004.10.006 Hurtado, 2007, A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke, Neurobiology of Disease, 26, 105, 10.1016/j.nbd.2006.12.005 Hurtado, 2013, Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke, Journal of Neurochemistry, 126, 819, 10.1111/jnc.12269 Zhuravin, 2015, The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer’s disease, Zh Nevrol Psikhiatr, 11, 77 Krupinski, 2012, Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1, Vascular Cell, 4, 20, 10.1186/2045-824X-4-20 Magni, 1996, Mini-Mental state examination: A normative study in Italian elderly population, European Journal of Neurology, 3, 198, 10.1111/j.1468-1331.1996.tb00423.x Martynov, 2015, Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke, Journal of Experimental Pharmacology, 7, 17, 10.2147/JEP.S63544 McShane, 2019, Memantine for dementia, The Cochrane Database of Systematic Reviews, 3 Pardossi-Piquard, 2006, Neprilysin activity and expression are controlled by nicastrin, Journal of Neurochemistry, 97, 1052, 10.1111/j.1471-4159.2006.03822.x Peskind, 2006, Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial, The American Journal of Geriatric Psychiatry, 14, 704, 10.1097/01.JGP.0000224350.82719.83 Putignano, 2012, Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome, Clinical Interventions in Aging, 7, 113, 10.2147/CIA.S29366 Rinaldi, 2003, Validation of the five-item geriatric depression scale in elderly subjects in three different settings, Journal of the American Geriatrics Society, 51, 694, 10.1034/j.1600-0579.2003.00216.x Robinson, 2006, Memantine: A review of its use in Alzheimer’s disease, Drugs, 66, 1515, 10.2165/00003495-200666110-00015 Rogawski, 2003, The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease, CNS Drug Reviews, 9, 275, 10.1111/j.1527-3458.2003.tb00254.x Secades, 2011, Citicoline: Pharmacological and clinical review, 2010 update, Revue Neurologique, 52, S1 Secades, 2019, Citicoline in the treatment of cognitive impairment, Journal of Neurology and Experimental Neuroscience, 5, 14, 10.17756/jnen.2019-047 Secades, 1995, CDP-choline: Pharmacological and clinical review, Methods and Findings in Experimental and Clinical Pharmacology, 17, 1 Secades, 2006, Citicoline: Pharmacological and clinical review, 2006 update, Methods and Findings in Experimental and Clinical Pharmacology, 28, 1 Synoradzki, 2019, Citicoline: A superior form of choline?, Nutrients, 11 Tang, 2013, Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk, The New England Journal of Medicine, 368, 1575, 10.1056/NEJMoa1109400 Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 Vogt, 2018, The gut microbiota-derived metabolite trimethylamine N oxide is elevated in Alzheimer’s disease, Alzheimer’s Research & Therapy, 10, 124, 10.1186/s13195-018-0451-2 World Alzheimer Report, 2013 Zhang, 2011, Protective effects and mechanisms of sirtuins in the nervous system, Progress in Neurobiology, 95, 373, 10.1016/j.pneurobio.2011.09.001